Michael Forstner
Overview
Explore the profile of Michael Forstner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sabatschus I, Bosl I, Prevoo M, Eerdekens M, Sprunken A, Galm O, et al.
Pain Ther
. 2021 Nov;
11(1):73-91.
PMID: 34792789
Introduction: Peripheral neuropathic pain (PNP) is difficult to treat. Several oral drugs are recommended as first-line treatments. Nevertheless, many patients cannot obtain sufficient pain relief or do not tolerate systemically...
2.
Fortuny J, Gersdorff G, Lassalle R, Linder M, Overbeek J, Reinold J, et al.
Pharmacoepidemiol Drug Saf
. 2021 Jun;
30(10):1447-1457.
PMID: 34181291
Purpose: This post-authorisation safety study estimated the risk of anaphylaxis in patients receiving intravenous (IV) iron in Europe, with interest in iron dextran and iron non-dextrans. Studies conducted in the...
3.
Forstner M
Per Med
. 2018 May;
9(5):507-514.
PMID: 29768767
The ongoing developments in personalized healthcare are opening new possibilities for the optimization of the benefit-risk profiles of drugs based on the stratification of patients. Beyond this straightforward application of...
4.
Riek U, Scholz R, Konarev P, Rufer A, Suter M, Nazabal A, et al.
J Biol Chem
. 2008 Mar;
283(26):18331-43.
PMID: 18372250
Heterotrimeric AMP-activated protein kinase (AMPK) is crucial for energy homeostasis of eukaryotic cells and organisms. Here we report on (i) bacterial expression of untagged mammalian AMPK isoform combinations, all containing...
5.
Leder L, Freuler F, Forstner M, Mayr L
Curr Opin Drug Discov Devel
. 2007 Apr;
10(2):193-202.
PMID: 17436555
The requirement for high levels of stable and functional proteins remains a bottleneck in many processes of modern drug discovery, including the high-throughput screening for novel active compounds or the...
6.
Forstner M, Leder L, Mayr L
Expert Rev Proteomics
. 2007 Feb;
4(1):67-78.
PMID: 17288516
The expression of high levels of stable and functional proteins remains a bottleneck in many scientific endeavors, including the determination of structures in a high-throughput fashion or the screening for...
7.
Klumpp M, Boettcher A, Becker D, Meder G, Blank J, Leder L, et al.
J Biomol Screen
. 2006 Jun;
11(6):617-33.
PMID: 16760365
This article discusses the development of homogeneous, miniaturized assays for the identification of novel kinase inhibitors from very large compound collections. In particular, the suitability of time-resolved fluorescence resonance energy...
8.
Philipps B, Rotmann D, Wicki M, Mayr L, Forstner M
Protein Expr Purif
. 2005 Jun;
42(1):211-8.
PMID: 15939308
Rapid expression of recombinant proteins for structure determination is one of the major challenges in pharmaceutical and academic research, since the number of potential drug targets has increased significantly in...
9.
Philipps B, Forstner M, Mayr L
Biotechnol Prog
. 2005 Jun;
21(3):708-11.
PMID: 15932246
Since the number of potential drug targets identified has significantly increased in the past decade, rapid expression of recombinant proteins in sufficient amounts for structure determination and modern drug discovery...
10.
Philipps B, Forstner M, Mayr L
Biotechniques
. 2004 Jan;
36(1):80-3.
PMID: 14740489
Recombinant baculoviruses derived from the Autographa californica nuclear polyhedrosis virus (AcNPV) are widely used to express heterologous genes in insect cells, but the use of the baculovirus expression vector system...